We investigated genes expression by retrograde axonal transport of replication-defective adenoviruses carrying genes for LacZ (AdLacZ) and Bcl-2 in motor neurons of transgenic mice expressing mutant human Cu/Zn superoxide dismutase (SOD1) gene containing a substitution of alanine for glycine at position 93. We found that intramuscular injection of AdLacZ into the tongue of mutant SOD1 transgenic mice and their wild-type littermates at various ages results in high expression of the transgene and similar time course of expression in hypoglossal cranial nerve nuclei, suggesting no difference in the behavior of the transgene expression between the two groups. Subsequently, we employed a molecular switching cassette for Bcl-2 designed to express Bcl-2 by Cre-loxP recombination using adenoviral vectors, and examined the COS7 and primary neuronal cells with the mutant SOD1 gene. The overexpression of Bcl-2 in
Introduction
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease characterized by the degeneration and loss of motor neurons in the anterior horns of the spinal cord, brainstem, and motor cortex. ALS leads to progressive muscular atrophy, muscle weakness of the upper and lower extremities, bulbar palsy such as dysarthria, dysphagia and tongue atrophy, and finally death within 3 to 5 years due to respiratory failure caused by the weakness of respiratory muscles. 1 Although the majority of cases is sporadic (SALS), about 5 to 10% of all ALS patients are familial forms (FALS), of which 15 to 20% have mutations in the gene encoding Cu/Zn superoxide dismutase (SOD1), located on chromosome 21. 2 The clinical course and pathologic features of SALS and FALS are similar, suggesting that they may show common pathogenic factors. both cells and the neuronal protection against staurosporineinduced apoptosis were observed, after dual infection of adenoviral vectors with cassette for Bcl-2 (AxCALNLBcl-2) and Cre recombinase (AxCANCre). After inoculation of AxCALNLBcl-2 followed by AxCANCre into the tongue of both mutant SOD1 transgenic mice and wild-type littermates, Bcl-2 was detected in both the injection site and the hypoglossal nuclei of brainstems, suggesting that this was the result of retrograde transport of AxCALNLBcl-2 and AxCANCre and expression of Bcl-2 by Cre recombinase in the hypoglossal nuclei. This strategy for delivery of exogenous genes such as Bcl-2 will be useful for studying neuronal death/survival and introducing foreign genes into postmitotic motor neurons, and in gene therapy for motor neuron diseases such as ALS. Gene Therapy (2001) 8, 977-986.
human SOD1 develop a severe and progressive motor neuron disease closely resembling human ALS and are available for study of the pathogenesis of ALS. The line of SOD1 transgenic mice containing an amino acid substitution of glycine at position 93 by alanine (G93A) has been reported to become paralyzed in one or more limbs due to loss of motor neurons from the spinal cord, with these mice dying by 4 to 5 months of age. 4, 5 Pathologic changes with vacuolar formation in the anterior horns of the spinal cord and in selected brainstem nuclei have been seen as early as less than 3 month at a pre-clinical stage. 6 Although the mechanisms by which ALS leads to motor neuron degeneration remain unclear, they are suggested to be associated with a deficiency of neurotrophic factors, excessive excitatory amino acids, excessive oxidative stress, and promoted apoptosis. 7 Therefore, neurotrophic factors, inhibitors of excitatory amino acids, anti-oxidative enzymes, and anti-apoptosis factors have been considered potential candidates for treating human motor neuron diseases. Some of these have been tested in therapeutic trials. In their investigation of gene-therapeutic modalities for motor neuron diseases, Aebischer et al 8 used encapsulated, genetically modified xenogeneic cells to deliver ciliary neurotrophic factor (CNTF) intrathecally into patients with ALS. Haase et al 9 demonstrated that adenovirus-mediated gene transfer of neurotrophin-3 (NT-3) or NT-3 and CNTF could produce substantial therapeutic effects in pmn (progressive motor neuropathy) mutant mice after intramuscular injection of the NT-3 or NT-3 and CNTF adenoviral vectors. Azzouz et al 10 demonstrated that local anti-apoptotic protein Bcl-2 expression in the spinal motor neurons could increase motor neuron survival and improve neuromuscular function in FALS mice after intraspinal injection of recombinant adeno-associated virus encoding Bcl-2. Thus, the possibility of somatic gene therapy as a viable therapeutic approach for motor neuron diseases has been investigated in several ways.
However, many improvements in efficacy, specificity, stability, regulatability and safety of gene transfer to central nervous system (CNS) in addition to muscle are required in order to realize gene therapy for motor neuron diseases including ALS.
11 Adenoviral vectors have several attractive properties as vehicles of gene transfer into CNS, [12] [13] [14] although it has become apparent that adenoviral vectors are immunogenic and can induce cytopathic effects. 15, 16 They can be prepared in high titer, can be used safely for human vaccination, and can accommodate relatively large gene inserts; they are particularly useful for infection and expression in terminally differentiated non-dividing cells, such as neurons. With regard to the specificity of gene transfer to CNS, the selective targeting of transgene expression to particular cells is required. This includes the use of cell-specific promoters, which drive the expression of genes encoding tissue-or cell-specific proteins, and choice of routes of gene delivery. As for a route of gene delivery, Ghadge et al 17 reported a specific gene delivery to CNS, mainly motor neurons, by means of retrograde axonal transport of adenoviral vectors in 4-to 6-week-old mice. They also observed the absence of inflammation in CNS for 10 days. Thus, retrograde transport in motor neurons may ultimately be useful in providing a route for gene therapy of motor neuron diseases, including ALS. With regard to the regulatability and safety of transgene expression in CNS, these include viral vectors using a drug-responsive promoter system 18, 19 and a molecular switch based on the Cre-loxP recombination system which is utilized in a gene activation and inactivation. 20 Since overexpression of transgene may sometimes be harmful, it should be important to be able to control the gene expression by this type of molecular switch system.
In the present study, we first investigated a gene expression by retrograde transport of adenoviral vectors containing LacZ gene (AdLacZ) in the hypoglossal cranial nerve nuclei after inoculation of AdLacZ into the tongue muscles of mutant SOD1 (G93A) transgenic mice and their wild-type littermates. We addressed the questions whether adenoviral vectors can be transported to affected motor neurons and express the transgene in these neurons, and whether the expression patterns of the transgene are similar between the two groups. Subsequently, we investigated the potential of a novel strategy for introducing exogenous Bcl-2 in a retrograde manner into motor neurons of mutant SOD1 transgenic mice, mediated by Cre-loxP recombination using adenoviral vectors.
Results
Detection of ␤-galactosidase (␤-gal) activity and LacZ mRNA in the hypoglossal nuclei We first examined mutant SOD1 transgenic mice in normal stages (within 14 days of age) and stage of the disease (16 and 20 weeks of age) according to previous reports, 6 as well as wild-type littermates. ␤-Gal activity was observed in the hypoglossal nuclei of the brainstem of both mutant SOD1 transgenic mice and wild-type littermates of all ages studied 2-7 days after inoculation of AdLacZ into the tongue (Figure 1a-c) brainstem showed selectively prominent ␤-gal activity in both sides of the hypoglossal nuclei after inoculation into the middle of the tongue (Figure 1a) , and in the right side of the hypoglossal nucleus after inoculation into the right side of the tongue (Figure 1b ). Beginning at 2 days after inoculation, each neuron showed ␤-gal activity in the cell bodies and neuron processes in the hypoglossal nuclei. Some specimens showed X-gal staining of the hypoglossal nerve roots in addition to neurons of the hypoglossal nuclei (Figure 1a ). Since the 16-and 20-week-old mutant SOD1 transgenic mice we employed had no clinical and pathologic changes, we next examined 37-weekold mutant SOD1 transgenic mice, which exhibited symptoms and signs of the disease, as well as wild-type littermates 2 weeks after inoculation of AdLacZ. ␤-Gal activity in the hypoglossal nuclei was detected in 37-week-old mutant SOD1 transgenic mice (Figure 1d ), as well as in wild-type littermates, but less in the number of ␤-gal-positive cells and intensity of the signals than in the younger mice shown in Figure 1a -c. Pathology of 37-week-old mutant SOD1 transgenic mice in brainstem showed mild loss of motor neuron and vacuolar degeneration. We also checked for differences in X-gal staining between mutant SOD1 transgenic mice and wild-type littermates, but found no such differences at any stage within the observation period.
Since we detected AdLacZ DNA in the brainstem sections using Southern blot analysis following PCR amplification (data not shown), we next employed in situ hybridization to detect LacZ mRNA for AdLacZ in the brainstem sections from wild-type littermates at the single cell level. Sections taken from between the two sections that showed ␤-gal activity at the right side of the hypoglossal nuclei were used for this experiment. In situ hybridization showed intense LacZ mRNA signals in some motor neurons of the hypoglossal nucleus at the right side when using antisense LacZ RNA probe ( Figure  1e ). There was a small signal corresponding to the left side of the hypoglossal nuclei, but there were also small signals in some neurons other than hypoglossal nuclei, suggesting background stain. The specificity of the hybridization experiment was also confirmed by the observation that almost no signal was detected in sections hybridized with the sense LacZ RNA probe (Figure 1f) , the antisense LacZ RNA probe after RNase treatment, and the antisense Neo RNA probe (data not shown).
Decrease of LacZ gene expression from AdLacZ in timecourse
We examined how long the gene introduced into motor neurons in a retrograde manner was expressed. We observed ␤-gal activity in the hypoglossal nuclei of the brainstem of both mutant SOD1 transgenic mice and wild-type littermates of 17-28 weeks of age at 1, 2, and 4 week(s) after inoculation of AdLacZ into the tongue (Figure 1g-j) . ␤-Gal activity was detected in the hypoglossal nuclei of all mice examined, but significantly declined with time after inoculation ( Figure 2 ). We also observed ␤-gal activity in part even outside the hypoglossal nuclei at 2 weeks after inoculation (Figure 1j ), suggesting exudation of ␤-gal enzyme protein from the cell bodies of neurons in the hypoglossal nuclei. We found no inflammation of these brainstem sections, in contrast to the pathology of tongue muscles injected with AdLacZ Gene Therapy showing infiltration of inflammatory cells, as well as degenerating muscle fibers.
Overexpression of Bcl-2 in COS7 and primary neuronal cells by infection of AxCALNLBcl-2 and AxCANCre
Adenoviral vectors containing a molecular switching cassette for Bcl-2 (AxCALNLBcl-2) are expected to express Bcl-2 only when adenoviral vectors containing Cre recombinase gene (AxCANCre) express a sufficient amount of Cre recombinase, as shown in Figure 3 . 20 Using this system, we first examined the expression of Bcl-2 in COS7 cells by infection of AxCALNLBcl-2 and AxCANCre with various multiplicities of infection (MOI). Western blot and immunocytochemical analyses showed that exogenous Bcl-2 was induced only when Cre recombinase was expressed (Figure 4a , b, d). The antihuman Bcl-2 monoclonal antibody we employed had strong reactivity for exogenous human Bcl-2 and weak cross-reactivity for endogenous Bcl-2 in COS7 cells (Figure 4a -c, e). We quantified the intensity of bands for exogenous and endogenous Bcl-2, using scanning densitometry and found that it was approximately nine times higher in exogenous Bcl-2 than in endogenous Bcl-2 ( Figure 4a ). In immunocytochemistry, we also found that there were much fewer signals for endogenous Bcl-2 when compared with exogenous Bcl-2 signals, indicating that endogenous Bcl-2 could be negligible (Figure 4a -c, e).
We next examined Bcl-2 expression in primary neuronal cells derived from mutant SOD1 transgenic mice by infection of AxCALNLBcl-2 and AxCANCre. We used 18-day embryos of mutant SOD1 transgenic mice to prepare primary neuronal cells. We used PCR to determine whether an embryo was a carrier or a non-carrier of mutant human SOD1 gene (Figure 5f ). Almost all the embryonic cultured cells prepared in the experiment showed immunoreactivity for microtubule-associated protein 2 (MAP-2) (Figure 5a ), indicating that the main population in the culture was of neuronal cell lineage. After infection with AxCALNLBcl-2 and AxCANCre, Bcl-
Figure 3 (a-c) The constructs of adenoviral vectors containing a molecular switching cassette for Bcl-2 (AxCALNLBcl-2) and expressing Cre recombinase (AxCANCre), and the strategy for activation of exogenous Bcl-2 by the Cre-loxP system. In AxCALNLBcl-2, a stuffer (neo-resistant gene) that lies between the CAG promoter and the coding region prevents the expression of Bcl-2 (a). The CAG promoter is a modified chicken ␤-actin promoter with cytomegalovirus immediate-early (CMV-IE) enhancer.
25 Adenovirus-mediated overexpression of Bcl-2 protects neurons with mutant SOD1 against staurosporineinduced apoptosis To define whether adenovirus-mediated overexpression of Bcl-2 induced by our system could protect cells against apoptotic stimuli, we examined the viability of primary neuronal cells derived from mutant SOD1 transgenic mice which were previously infected with AxCALNLBcl-2 and AxCANCre against staurosporine (STS)-induced apoptosis. Primary neuronal cells with mutant human SOD1 gene infected with AxCALNLBcl-2 and AxCANCre were treated with 1 m STS in culture medium. Twenty-four hours later, apoptotic cells were identified with propidium iodide staining which showed, under the microscope, both red nuclear fluorescence and the condensation of nuclear chromatin (Figures 6a-f,  arrows) . We counted the number of viable cells in certain areas and found that it was significantly higher in neuronal cells with 50 MOI of AxCALNLBcl-2 and 1 MOI of AxCANCre in which Bcl-2 was expressed, compared with those without AxCALNLBcl-2 and AxCANCre (52.8% increase in viable cells, P Ͻ 0.001) (Figure 6g ). Infection of 5 MOI of AxCALNLBcl-2 and 0.1 MOI of AxCANCre was likely to be insufficient to express Bcl-2 for protection of primary neuronal cells against STSinduced apoptosis. Thus, the result showed that overexpression of Bcl-2 induced by our system could protect neurons against STS-induced apoptosis.
Bcl-2 transgene expression within the tongue and hypoglossal nuclei of mutant SOD1 transgenic mice We attempted to determine whether the injection of AxCALNLBcl-2 followed by AxCANCre into the tongue muscles of mutant SOD1 transgenic mice and wild-type littermates would result in retrograde transport of the adenoviruses into the hypoglossal nuclei, and expression of Bcl-2 gene in these nuclei. In the in vivo mice experiment, AxCANCre was inoculated 24 h after injection of AxCALNLBcl-2 at the same place in the tongue. Bcl-2 was detected in some of the tongue muscle fibers of both mutant SOD1 transgenic mice (Figure 7a ) and wild-type littermates at the injection site, but was diffusely distributed to some extent. Bcl-2 was also observed in the hypoglossal nuclei of the brainstems of both mutant SOD1 transgenic mice (Figures 7c, e) and wild-type littermates (Figure 7d ) after inoculation of AxCALNLBcl-2 followed by AxCANCre into the tongue muscles. The tongue and brainstem sections showed only weak signals for antihuman Bcl-2 antibody after inoculation of AxCALNLBcl-2 alone into tongue muscles (Figure 7b, g ) or without inoculation (Figure 7h ), which were probably non-specific or endogenous Bcl-2 signals and obviously differentiated from exogenous human Bcl-2. We found no inflammation of the brainstem derived from either group of mice after infection with adenoviral vectors.
To examine whether Bcl-2 protein in hypoglossal nuclei was the result of retrograde axonal flow of AxCALNLBcl-2 and AxCANCre or Bcl-2 protein produced in tongue muscles inoculated with both vectors, we employed PCR and Southern blot analysis to detect Bcl-2 DNA fragment after Cre-loxP recombination. We designed primer pairs which were able to amplify Bcl-2 DNA only when the Cre recombinase derived from AxCANCre mediated excisional deletion of a stuffer region flanked by a pair of loxP sites as shown in Figure  3 . The Bcl-2 DNA fragment was amplified in the tongue and brainstem from the mutant SOD1 transgenic mice (Figure 8, lanes 1 and 4) and wild-type littermates (data not shown) when both AxCALNLBcl-2 and AxCANCre were infected into the tongue muscles.
Gene Therapy 
Discussion
In the present study, we found a gene (LacZ gene) expression by retrograde transport of adenoviral vectors in motor neurons of mutant SOD1 transgenic mice as well as healthy older mice. Subsequently, we established a novel strategy for introducing exogenous Bcl-2 into in vitro and in vivo motor neurons of mutant SOD1 transgenic mice using retrograde transport and a Cre-loxP recombination system by adenoviral vectors.
Since ALS usually occurs during middle age, we attempted to determine whether adenoviral vectors could
Figure 7 Detection of immunoreactivity for Bcl-2 in the tongue muscle fibers (a, b) and hypoglossal nuclei (c-h) of mutant SOD1 transgenic mouse (a, c, e-h) and wild-type littermate (b, d) after inoculation of AxCALNLBcl-2 followed by AxCANCre (a, c-f), AxCALNLBcl-2 alone (b, g) or without inoculation (h); (e) is a higher magnification of (c); (e, f) are the identical fields stained with immunofluorescence for Bcl-2 (e) and H&E staining (f). These Bcl-2-positive cells were large motor neurons of the hypoglossal nuclei as revealed by H&E staining shown by each arrowhead. Scale bars, 50 m.
be transported in a retrograde manner at any age. Retrograde transport of adenoviral vectors was observed as late as 37 weeks of age in both mice, indicating adenoviral vectors could be transported in a retrograde manner even in the manifested motor neurons. We also checked for differences in ␤-gal activity between mutant SOD1 transgenic mice and wild-type littermates, but found no such differences at any stage within the observation period. Warita et al 21 reported delivery of AdLacZ in a few motor neurons of cervical spinal cord in one mutant SOD1 (G93A) transgenic mouse at 27 weeks of age, using X-gal staining after injection of AdLacZ into brachial muscle. Although the pathologic changes consisting of vacuolar formation in the anterior horns of the spinal cord and in selected brainstem nuclei have been observed in the pre-clinical stage as early as 3 months of age or less, 6 no vacuolar formation was observed in the mutant SOD1 transgenic mice used in our experiments until at least 24 weeks of age, as previously reported. 22 In addition to restricting transgene expression to motor neurons, maintaining long-term expression is one of the major goals for gene therapy in the motor neuron diseases. Transgene expression using adenoviral vectors is transient in most in vivo systems because of cellular and humoral immune responses triggered following the administration of adenoviral vectors, 15, 16 although the brain is traditionally considered an immunologically privileged organ. Most studies on the route of delivery of vectors have utilized local intracerebral or intraventricularly stereotactic injections of vectors, which have limited clinical applicability. Byrnes et al 15 reported that there was a heavy infiltration of leukocytes at 2 days after stereotactic injection of AdLacZ into the rat striatum, and in spite of the inflammatory response, the expression of ␤-gal activity in neural cells was observed for at least 2 months, although the expression declined with time. In the present study, we observed no inflammation in the brainstem for 4 weeks after inoculation. To address whether retrograde transport of recombinant genes is advantageous in terms of immunogenicity, we investigated the stability of transgene expression in motor neurons following intramuscular injection of adenoviral vectors. However, we obtained the results that ␤-gal activity in the hypoglossal nuclei declined with time, suggesting down-regulation of transcription of the transgene in motor neurons. Adenoviral vectors containing a viral promoter such as the cytomegalovirus (CMV) we employed in this study or Rous sarcoma virus have been shown to have high transcription levels, but to have short-term efficiency of viral promoter suggested by down-regulation of transcription through cellular defense mechanisms. 23 Navarro et al 24 reported that ␤-gal gene expression remained stable for 3. months and was detectable for 6 months after administration of AdLacZ with promoter of neuron-specific enolase. Thus, a promoter we employ should be an important factor for transgene expression. In Bcl-2 gene expression, we employed the CAG promoter, which is a modified chicken ␤-actin promoter with CMV immediate-early enhancer, 25 instead of the CMV promoter. Although we did not examine the time course of Bcl-2 gene expression in the present study, it will be necessary to determine which promoter is most suitable for motor neurons.
Based on the observation of AdLacZ, we attempted to express a protective gene for long-term survival in motor neurons of mutant SOD 1 transgenic mice in vitro and in vivo in the next step of the development of a gene therapy for motor neuron diseases. Recent studies have shown that mutant SOD1 promotes apoptosis in neuronal cells in contrast to the anti-apoptotic properties of wild-type SOD1. 26 Overexpression of Bcl-2 in the progeny from crosses between FALS transgenic and Bcl-2 transgenic mice has been shown to prolong the survival of FALS mice, 27 and local Bcl-2 expression in the spinal motor neurons has been seen to increase motor neuron survival in FALS mice after intraspinal injection of recombinant adeno-associated virus. 10 Thus, Bcl-2 was a possible candidate to enlist in the prevention or delay of motor neuron death.
We employed a molecular switching cassette for Bcl-2 expression by means of Cre-loxP recombination using adenoviral vectors, and demonstrated Bcl-2 expression in COS7 and primary neuronal cells, and in vivo motor neurons in mice. The Cre-loxP recombination system had been successfully utilized in a gene activation and inactivation strategy in transgenic mice, ES cells, and cultured cells. However, applications of the Cre-loxP system were still very limited because only a small fraction of cells could be subjected to gene activation by Cre recombinase produced as a result of DNA transfection or electroporation. Kanegae et al 28 reported that Cre-mediated gene activation could be achieved in virtually 100% of a cultured cell population on cell chromosomes by using adenoviral vectors expressing a modified Cre gene tagged with a nuclear localization signal. 28, 29 Sato et al 20 established a strategy for introducing exogenous Bcl-2 into neuronal cells in vitro that is mediated by Cre-loxP recombination using adenoviral vectors. Thus, the CreloxP recombination system using adenoviral vectors enables various sorts of gene manipulations mediated by the Cre recombinase to be efficiently performed in various cells, both in vitro and in vivo. Bcl-2 was originally discovered as a protein product of the proto-oncogene, and increased Bcl-2 expression is a common feature of many types of human malignancies, which implies that Bcl-2 plays an important role in tumorigenesis. 30 Although Bcl-2 should be useful in the protection of various cells against death related to apoptosis, the overexpression of Bcl-2 may become harmful for the subjects introduced with Bcl-2 gene. Therefore, it would be important for us to be able to control expression of the introduced gene in vivo, such as via the inactivation of gene expression by Cre-loxP recombination using recombinant adenoviral vectors. In our present study, we activated the Bcl-2 gene; however, it is also possible to
Gene Therapy inactivate the gene by changing the location of a pair of loxP sites. To determine whether Bcl-2 produced by this Cre-loxP recombination system was functional, we examined whether overexpression of Bcl-2 could protect primary neuronal cells with mutant human SOD1 gene against STS-induced apoptosis. Most studies on cell survival by Bcl-2 have reported using cell lines transfected with mutant SOD1 cDNA, 31, 32 and a few using primary neuronal cultures. 33 In our experiment, we used primary neuronal cells with SOD1 mutation separated from wildtype neuronal cells. We wanted to compare the difference between primary neuronal cells with SOD1 mutation and those with the wild-type in protection by overexpression of Bcl-2 using various apoptotic stimuli and conditions. The results with regard to their protection against STSinduced apoptosis appeared to be similar between the two primary neuronal cells. Further study is necessary to elucidate whether there is any difference in cell survival between the two cells after a variety of apoptotic stimuli.
We also considered retrograde transport as a route for the introduction of the genes. The most important question was whether two kinds of adenoviral vectors, AxCALNLBcl-2 and AxCANCre, were transported in a retrograde manner in the same motor neurons and expressed the Bcl-2 gene after inoculation into the tongue muscles of mutant SOD1 transgenic mice. We demonstrated that Bcl-2 was observed in the hypoglossal nuclei, suggesting the result of retrograde transport of AxCALNLBcl-2 and AxCANCre and expression of Bcl-2 by Cre recombinase in these nuclei. Although only a few groups have reported the delivery of a reporter gene such as LacZ to motor neurons by retrograde transport of adenoviral vectors, 17, 21, 34 retrograde transport as a route of introduction of the gene seems to be one of the most attractive ways, especially in motor neuron diseases.
To our knowledge, this study describes the first successful retrograde transfer and expression of a specific gene such as Bcl-2 (not a reporter gene) into motor neurons of mutant SOD1 transgenic mice in vivo under the control of the Cre-loxP system for specific gene activation. Namikawa et al 35 have reported that Akt/protein kinase B prevented injury-induced motor neuron death and accelerated axonal regeneration using the Cre-loxP system. In the present study, we did not show the effect of exogenous Bcl-2 in vivo motor neurons of mutant SOD1 transgenic mice; however, such studies have been ongoing. Combination gene therapy using specific genes such as neurotrophic factors, inhibitors of excitatory amino acid, radical scavengers, and inhibitory factors for neuronal apoptosis in both inoculated and retrogradely transported sites, and applications of the Cre-loxP system may constitute powerful tools for treatment of motor neuron diseases.
Materials and methods

Recombinant adenoviruses
The preparation of AdLacZ, AxCALNLBcl-2 and AxCANCre has been described elsewhere. 20, 36, 37 Human Bcl-2 cDNA was kindly provided by Dr SJ Korsmeyer (Harvard Medical School, Boston, MA, USA). The viruses were grown in 293 cells and purified by CsCl gradient centrifugation. Virus titer was determined by plaque assay, and concentrated virus was stored at −80°C.
Animals
Transgenic mice carrying a high copy number of a mutant allele human SOD1 (G93A) gene [B6SJL-TgN (SOD1-G93A)1Gur] 4 and their wild-type non-transgenic littermates (B6SJL) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA), and housed under an atmosphere free of known pathogens. Selective breeding maintained the mutant SOD1 (G93A) transgene in the hemizygous state in B6SJLF1 hybrids. Genomic DNA was extracted from a tail biopsy sample. Genotype analysis of the SOD1 mutation was performed by means of PCR with a set of primers as described by Rosen et al. 2 Mutant SOD1 transgenic mice and wild-type littermates were used for inoculation of AdLacZ at various ages (for transgenic mice, 7 days, 14 days, 16 Cell cultures COS7 cells (monkey kidney cells) were maintained in vitro in Dulbecco's modified Eagle's medium (DMEM, Gibco-BRL, Gaithersburg, MD, USA) and supplemented with 10% fetal calf serum (FCS, JRH Biosciences, Lenexa, KS, USA), 100 IU/ml penicillin, and 100 mg/ml streptomycin (Sigma Chemical, St Louis, MO, USA). Primary neuronal cells were prepared from 18-day embryos of mutant SOD1 transgenic mice. During genotype analysis, embryos were kept on ice in calcium/magnesium-free Hank's balanced salt solution (HBSS, Gibco-BRL). Fetal cerebral cortices with mutant SOD1 were dissected and then digested with calcium/magnesium-free HBSS containing 0.25% trypsin for 15 min at 37°C. Tissues were dissociated by repeated trituration. The cells were then seeded at a density of 1.6 × 10 6 cells in a 60-mm dish (Becton Dickinson, Franklin Lakes, NJ, USA) coated with poly-l-ornithine (Sigma Chemical), and cultured in growth medium at 37°C in a humidified atmosphere of 5% CO 2 and 95% room air. The growth medium consisted of DMEM/F-12 (Gibco-BRL) supplemented with B27 supplement (Gibco-BRL), 100 IU/ml penicillin, and 100 mg/ml streptomycin. To inhibit the growth of glial cells, 10 m cytosine arabinoside (Sigma Chemical) was added to the medium on culture day 4.
Histochemistry and immunofluorescence
The mice were killed 2-5 days, 1, 2, and 4 week(s) after inoculation of AdLacZ and 2 days after inoculation of AxCANCre following AxCALNLBcl-2 described above, and perfused with phosphate buffered saline (PBS) followed by 4% paraformaldehyde. The tongues and whole brains were removed and fixed in 4% paraformaldehyde for 6-12 h at 4°C, placed in 30% sucrose overnight, mounted with OCT compound, and then stored at −80°C until use for the following study. The sections of brainstem and tongue on glass slides were stained first with X-gal, then with hematoxylin and eosin (H&E) staining. For immunofluorescence, the sections were blocked with blocking kit (ScyTeK, West Logan, UT, USA) and immunostained with anti-human Bcl-2 monoclonal antibody (1:40 dilution) (Dako, Glostrup, Denmark) and antibody against mouse (1:200 dilution) conjugated to FITC (Jackson ImmunoResearch Laboratories, West Grove, PA, USA).
Cultured cells grown on four chamber glass slides (Becton Dickinson) were incubated with AxCALNLBcl-2 and AxCANCre for 2 h at various MOI. After 48 h, COS7 and primary neuronal cells were fixed with 4% paraformaldehyde, washed three times with PBS, and blocked with 10% normal goat serum and 0.1% Triton-X in PBS for 30 min. The cells were then incubated with a 1:100 dilution of anti-human Bcl-2 monoclonal antibody (Dako), and a 1:100 dilution of anti-MAP-2 goat polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immunoreacted primary antibody was detected using a 1:200 dilution of anti-mouse IgG antibody-FITC for Bcl-2 and a 1:500 dilution of anti-goat IgG antibody-Cy3 (Jackson ImmunoResearch Laboratories). The cells on glass slides were examined using confocal laser scan microscopy (LSM410, Carl Zeiss microscopy, Jena, Germany).
Detection of Bcl-2 DNA fragment in tissue sections
After immunostain of the sections of brainstem and tongue for Bcl-2 on glass slides, these specimens were scraped off into microcentrifuge tubes. Then the specimens were incubated to extract DNA in 100 l of lysis buffer containing 10 mm Tris HCl (pH 8.3), 50 mm KCl, 2.5 mm MgCl 2 , 0.45% Tween-20, and 0.1 mg proteinase K at 55°C for 2 h, then boiled for 10 min. Ten microliters of the solution was used for PCR amplification. A set of primers (primers A, 5Ј-CTGCTAACCATGTTCATGCC-3Ј and B, 5Ј-CCCTCTGCGACAGCTTATAA-3Ј) was used for PCR amplification to detect Bcl-2 gene only after recombination in the brainstem and tongue muscle tissue sections (Figure 3 ). Fifty microliters of the reaction mixtures contained 200 m dNTP, 1.0 m of each primer, 50 mm KCl, 10 mm Tris HCl (pH 8.3), 2.5 mm MgCl 2 , and 2.5 U of Taq polymerase. After 45 cycles (1 min at 94°C, 1 min at 52°C, and 1 min at 72°C), the PCR product was electrophoresed on a 1.2% agarose gel and transferred to a nylon membrane filter (Amersham Pharmacia Biotech, Buckinghamshire, UK) in 0.4 N NaOH and 1.5 m NaCl. The membrane was UV-crosslinked and hybridized with a Bcl-2 probe ( Figure 3 ) labeled with alkaline phosphatases (AP), and kept at 55°C overnight. The blot was washed in primary wash buffer (2 m urea, 0.1% SDS, 50 mm Na phosphate (pH 7.0), 150 mm NaCl, 1 mm MgCl 2 , 0.2% blocking reagent) and secondary wash buffer (50 mm Tris HCl (pH 10.0), 100 mm NaCl, 2 mm MgCl 2 ) and then the band corresponding to Bcl-2 was detected using a CDP-Star chemiluminescent detection kit (Amersham Pharmacia Biotech) according to the manufacturer's instructions.
Probes and in situ hybridization for detection of LacZ mRNA on tissue sections We used pBCKS+/− containing CMV-LacZ fragment (pBC LacZ) for RNA probes. The pBC LacZ was linearized with KpnI or NotI, transcribed with either T7 or T3 RNA polymerase, and labeled with digoxigenin (DIG) UTP (Boehringer Mannheim, Mannheim, Germany) to yield the sense or antisense probe for LacZ mRNA, respectively. The DIG-labeled LacZ RNA probes were prepared according to the manufacturer's instructions and were used in in situ hybridization for detection of LacZ mRNA in brain sections. We also prepared an antisense Neo RNA probe as a negative control, as described above.
In situ hybridization was performed as described previously, with slight alteration of the detection steps. 38, 39 Briefly, 30 m-thick sections from the mouse brain were placed on poly-l-lysine coated glass slides, fixed in freshly prepared 4% paraformaldehyde, and washed twice in 2 × SSC ( 0.3 m NaCl and 0.03 m Na-citrate). Sections were then treated with proteinase K (5 g/ml) for 10 min at room temperature. After washing in 2 × SSC, the samples were placed for 1 h in prehybridization solution. One each of the antisense, sense LacZ RNA, and antisense Neo RNA probes labeled with DIG was combined with hybridization solution containing 10% dextran sulfate so that the final probe concentration was 200 ng/ml of the hybridization solution. The sections were overlaid with the hybridization solution and incubated at 42°C for 18 h.
After hybridization, the samples were rinsed in 2 × SSC for 1 h at room temperature and treated with RNase (30 g/ml) to avoid unbounded RNA probe. After RNase treatment, the slides were washed in 2 × SSC at room temperature and in 0.1 × SSC for 1 h at 50°C. Then the sections were immersed with blocking solution for 45 min at room temperature. For detection, the sections were incubated with anti-DIG antibody conjugated to AP, followed by color reaction using NBT and BCIP.
Estimation of ␤-gal-positive neurons
We estimated ␤-gal-positive cells in the hypoglossal nuclei of the brainstem of mutant SOD1 transgenic mice and wild-type littermates of 17-28 weeks of age at 1, 2, and 4 week(s) after inoculation of AdLacZ into the tongue. We used between three and seven mice for each group of mutant SOD1 transgenic mice and wild-type littermates at 1, 2, and 4 week(s) after inoculation of AdLacZ into the tongue. In each mouse, we counted ␤-gal-positive neurons on two serial brainstem sections with higher signals.
Western blot analysis COS7 cells were infected with AxCALNLBcl-2 and AxCANCre at various MOI for 1 h and then harvested for 48 h after inoculation. The samples were lysed in 100 l of lysis buffer (2% SDS, 5% ␤-mercaptoethanol, 4 mm EDTA, 40 mm Tris HCl (pH 6.8), 0.24 m glycine, 40% glycerine, and 0.001% bromophenol blue (pH 8.5)). The samples were boiled for 5 min and 5 l of the cell lysates were subjected to electrophoresis on 15% SDS-PAGE gels at 30 mA for 3 h. Following transfer to nitrocellulose membranes (Schleicher and Schuell, Keene, NH, USA), the specimens were blocked with 5% non-fat dried milk in PBS overnight at 4°C and then incubated with the primary antibody in blocking buffer for 1 h at room tem-perature. The membrane was washed three times in TTBS (20 mm Tris HCl (pH 7.5), 500 mm NaCl, 0.05% Tween 20) probed with the secondary antibody in blocking buffer for 30 min at room temperature, and washed again in TBS (20 mm Tris HCl (pH 7.5), 500 mm NaCl). The membranes were processed according to the enhanced chemiluminescence detection protocol (Amersham Pharmacia Biotech). The primary antibodies used were monoclonal anti-human Bcl-2 diluted 1:500 (Dako), monoclonal anti-Cre recombinase diluted 1:1000 (BAbCO, Richmond, CA, USA), and monoclonal anti-mouse ␤-actin diluted 1:1000 (Sigma Chemical). The second antibody used was peroxidase-conjugated, goat anti-mouse IgG (Amersham Pharmacia Biotech). Films were scanned on an Epson GT-9000 scanner, and intensity of bands was quantified by using the NIH Image 1.60 software.
Cell viability
Primary neuronal cells were cultured for 4 days and then infected with AxCALNLBcl-2 and AxCANCre for 24 h before STS exposure. The effect of Bcl-2 gene expression on the viability of cells with the SOD1 mutation was determined using propidium iodide (Molecular Probes, Inc., Eugene, OR, USA) after STS exposure. Twenty-four hours later, apoptotic cells were identified as red nuclear fluorescence with chromatin condensation, under confocal laser scan microscopy (LSM410, Carl Zeiss).
Statistical studies
Statistical comparisons were performed using one-way or two-factorial analysis of variance (ANOVA) followed by Fisher's protected least significant difference test.
